Tokyo Tape
Sign in
← Carna Biosciences

Quarterly report · Q3

4572.TEDINET S100PEWN
Period2022-01-01 → 2022-09-30
Filed2022-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥1.1bn2022-01-01 → 2022-09-30Cons.Net sales
Revenue¥2.0bn2021-01-01 → 2021-12-31Cons.Net sales (5-year summary)
Revenue¥637m2021-01-01 → 2021-09-30Cons.Net sales
Operating income−¥754m2022-01-01 → 2022-09-30Cons.Operating income
Operating income−¥1.2bn2021-01-01 → 2021-09-30Cons.Operating income
Ordinary income−¥736m2022-01-01 → 2022-09-30Cons.Ordinary income
Ordinary income−¥523m2021-01-01 → 2021-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.2bn2021-01-01 → 2021-09-30Cons.Ordinary income
Profit before tax−¥779m2022-01-01 → 2022-09-30Cons.Income before income taxes
Profit before tax−¥1.2bn2021-01-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)−¥795m2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥534m2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.2bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income−¥795m2022-01-01 → 2022-09-30Cons.Profit loss
Net income−¥1.2bn2021-01-01 → 2021-09-30Cons.Profit loss
Total assets¥4.5bnat 2022-09-30Cons.Assets
Total assets¥5.4bnat 2021-12-31Cons.Assets
Total assets¥4.2bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥604mat 2022-09-30Cons.Liabilities
Total liabilities¥1.1bnat 2021-12-31Cons.Liabilities
Net assets / equity¥3.9bnat 2022-09-30Cons.Net assets
Net assets / equity¥4.3bnat 2021-12-31Cons.Net assets
Net assets / equity¥3.5bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.7bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥3.8bnat 2021-12-31Cons.Cash and deposits
EPS (basic)¥-58.562022-01-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-31.922022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-42.12021-01-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-94.242021-01-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-31.682021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio86.5%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio79.3%at 2021-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio82.4%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 10
SegmentItemPeriodValue
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥286m
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥286m
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥1.1bn
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥810m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥810m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2022-01-01 → 2022-09-30¥336m
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentsegment profit2021-01-01 → 2021-09-30−¥1.4bn
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2021-01-01 → 2021-09-30¥637m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2021-01-01 → 2021-09-30¥637m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2021-01-01 → 2021-09-30¥199m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 315
ItemContextValueUnit
Other nclPrior1YearInstant4508000JPY
Other nclCurrentQuarterInstant17978000JPY
Noncurrent liabilitiesPrior1YearInstant342332000JPY
Noncurrent liabilitiesCurrentQuarterInstant234266000JPY
LiabilitiesPrior1YearInstant1116988000JPY
LiabilitiesCurrentQuarterInstant604470000JPY
Capital stockPrior1YearInstant1056953000JPY
Capital stockCurrentQuarterInstant1231110000JPY
Capital surplusPrior1YearInstant4808163000JPY
Capital surplusCurrentQuarterInstant4982320000JPY
Retained earningsPrior1YearInstant-1572951000JPY
Retained earningsCurrentQuarterInstant-2368169000JPY
Treasury stockPrior1YearInstant-222000JPY
Treasury stockCurrentQuarterInstant-222000JPY
Shareholders equityPrior1YearInstant4291942000JPY
Shareholders equityCurrentQuarterInstant3845039000JPY
Valuation difference on available for sale securitiesPrior1YearInstant-630000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant-2347000JPY
Deferred gains or losses on hedgesPrior1YearInstant6578000JPY
Deferred gains or losses on hedgesCurrentQuarterInstant37366000JPY
Foreign currency translation adjustmentPrior1YearInstant7841000JPY
Foreign currency translation adjustmentCurrentQuarterInstant55210000JPY
Valuation and translation adjustmentsPrior1YearInstant13789000JPY
Valuation and translation adjustmentsCurrentQuarterInstant90229000JPY
Subscription rights to sharesPrior1YearInstant9840000JPY
Subscription rights to sharesCurrentQuarterInstant7999000JPY
Net assetsPrior1YearInstant4315572000JPY
Net assetsCurrentQuarterInstant3943268000JPY
Liabilities and net assetsPrior1YearInstant5432560000JPY
Liabilities and net assetsCurrentQuarterInstant4547738000JPY
Net salesPrior1YTDDuration636512000JPY
Net salesCurrentYTDDuration1095607000JPY
Cost of salesPrior1YTDDuration95794000JPY
Cost of salesCurrentYTDDuration123674000JPY
Gross profitPrior1YTDDuration540717000JPY
Gross profitCurrentYTDDuration971932000JPY
Selling general and administrative expensesPrior1YTDDuration1709734000JPY
Selling general and administrative expensesCurrentYTDDuration1725638000JPY
Operating incomePrior1YTDDuration-1169016000JPY
Operating incomeCurrentYTDDuration-753705000JPY
Interest income noiPrior1YTDDuration90000JPY
Interest income noiCurrentYTDDuration127000JPY
Dividends income noiPrior1YTDDuration298000JPY
Dividends income noiCurrentYTDDuration307000JPY
Subsidy income noi bountyPrior1YTDDuration1346000JPY
Subsidy income noi bountyCurrentYTDDuration1000000JPY
Subsidy income noiPrior1YTDDuration7200000JPY
Subsidy income noiCurrentYTDDuration－JPY
Foreign exchange gains noiPrior1YTDDuration597000JPY
Foreign exchange gains noiCurrentYTDDuration20047000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-12-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass